Printer Friendly

Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women.

The roles of natriuretic peptides in promoting vasodilation and natriuresis are well known (1, 2), and assays for both the active form of B-type natriuretic peptide (BNP) [6] and the inactive amino-terminal fragment of the peptide (NT-proBNP) have gained widespread acceptance as tools for the diagnosis of heart failure in the acute-care setting (3, 4). B-type natriuretic peptides also play an important role in regulating lipolysis in adipocytes (5, 6), and several cross-sectional epidemiological studies have reported inverse associations between BNP concentrations and body mass index (BMI), glucose concentrations, measures of insulin resistance, and the number of components of the metabolic syndrome (7-9).

However, prospective studies of the relationship between BNP concentrations and incident type 2 diabetes mellitus (T2DM) are scarce and inconsistent (10-12). To better understand the possible metabolic effects of the natriuretic peptide system, we first measured baseline concentrations of NT-proBNP and several other plasma markers of metabolism and inflammation in healthy middle-aged and older women enrolled in the Women's Health Study (WHS) (13). We then examined correlations between these biomarkers and NT-proBNP concentrations and tested for evidence of association between NT-proBNP concentrations and incident T2DM in a prospective case-cohort study of women from the WHS. We also conducted a series of analyses to determine if common genetic variants previously reported to associate with NT-proBNP concentrations and T2DM demonstrated similar evidence of association in our cohort of women.

Materials and Methods


Study participants were enrolled in the WHS, a completed randomized, double-blind, placebo-controlled 2-by-2 factorial trial of aspirin and vitamin E in the prevention of cardiovascular disease and cancer among 39 876 female health professionals age 45 years and older (13). Enrollment began in 1992, participants were free of cardiovascular disease at baseline, and a total of 28 345 women provided a blood sample at baseline. Among these, 19 871 (70.1%) were fasting at time of sample collection. These samples were centrifuged and stored in liquid nitrogen until laboratory analysis. The randomized portion of the study was completed in March 2004, and women were invited to participate in continued observational follow-up. Participants have been followed continuously for incident cardiovascular disease and T2DM. Three different subgroups of WHS participants were identified for the analyses of NT-proBNP and incident T2DM, common genetic variation and NT-proBNP concentrations, and common genetic variation and incident T2DM components of this study.


For the prospective analysis of NT-proBNP concentrations and incident T2DM, all subjects were selected from among women without baseline-diagnosed diabetes [absent self report of T2DM and hemoglobin A1c (Hb [A.sub.1c]) < 6.5%] and with adequate baseline fasting blood specimens. We designed a case-cohort study by first selecting a random sample of incident T2DM cases (n = 491) from among the entire WHS cohort. Cases were defined as nondiabetic WHS participants who provided baseline blood specimens and subsequently developed newly diagnosed T2DM. A randomly selected subcohort of women with available blood specimens was then chosen as a reference risk set (n = 561). The sampling technique excluded women with baseline T2DM, but women who developed T2DM during follow-up were eligible for inclusion in the reference subcohort. By chance, 50 such women were selected for the reference subcohort, so the case-cohort set included 491 incident T2DM cases and 511 noncases. The selection of the reference subcohort was stratified by race/ethnicity (white vs nonwhite) as well as age (5-year strata) to approximately match the distribution among cases of T2DM (included in this study) as well as a separate group of cases of incident cardiovascular disease (not included in this study).


To validate previously reported associations between the common genetic variants in the natriuretic peptide precursor A (NPPA) (7) and natriuretic peptide precursor B(NPPB) genes and NT-proBNP, we used data from women selected for the reference subcohort who also had genotyping performed as part of the larger Women's Genome Health Study, which is a subset of the women enrolled in the WHS. The Women's Genome Health Study includes >25 000 women with available genotyping data. The study is described in detail elsewhere (14). Of the 561 women selected for inclusion in the reference subcohort for this study, 458 were of European ancestry and had both genotyping information and available NT-proBNP concentrations.


To test whether common variation in NPPA and NPPB was associated with incident T2DM in the WHS and Women's Genome Health Study, we identified all women of European ancestry with genotyping information who had an Hb A1c <6.5% and did not have a clinical diagnosis of T2DM at baseline. In total, there were 22 607 women in this cohort with 1372 cases of incident T2DM.


Incident T2DM was identified in an identical fashion for all participants in the WHS and in this study. Possible cases of incident T2DM were initially identified by self-report on annual questionnaires that asked if and when the participant had been diagnosed with T2DM since baseline. Self-reported cases were then confirmed by physician-administered telephone interviews using the American Diabetes Association diagnostic criteria (15) or a self-administered supplemental questionnaire. In a validation study, both interview-based and supplemental questionnaire-based confirmation yielded positive predictive values >90% in comparison to medical record review (16). In particular, the positive predictive value of the supplemental questionnaire was 99% (95% CI 97%-100%). Overall, in 95% of all-self-reported T2DM events, sufficient information for confirmation or disconfirmation of the endpoint was obtained, and only confirmed cases were used in this analysis. Because the prevalence of undiagnosed T2DM among middle-aged US adults is so high, and because this analysis was designed to investigate the role of NT-proBNP as a determinant of future disease, we limited our sample to individuals with a baseline Hb [A.sub.1c] <6.5%.


Plasma NT-proBNP was measured using an electrochemiluminescent immunoassay assay provided by Roche Diagnostics. The assay has day-to-day variability at concentrations of 175, 434, and 6781 ng/L of 3.2%, 2.4%, and 2.2%, respectively. In addition to NT-proBNP, plasma samples were measured for insulin, leptin, resistin, interleukin-6, free fatty acids, oxidized LDL cholesterol, creatinine, Hb A1c, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), and soluble intercellular adhesion molecule 1 in a core laboratory certified by the National, Heart, Lung, and Blood Institute/CDC and Prevention Lipid Standardization Program. Details of the assays used and measures of day-to-day variation are available upon request.

DNA samples were genotyped with the Infinium II technology from Illumina (Human HAP300 panel) as previously described (14). All samples were required to have successful genotyping using the BeadStudio v. 3.3 software (Illumina) for at least 98% of the single nucleotide polymorphisms (SNPs). SNPs with call rates < 90% and samples with percentage of missing genotypes >2% or that deviated from Hardy-Weinberg equilibrium were removed from the analysis. We identified 4 single nucleotide polymorphisms (rs198358, rs5068, rs632793, and rs198389) that had been associated with NT-proBNP concentrations, atrial natriuretic peptide concentrations, or aspects of the metabolic syndrome and/or T2DM in the literature (10,17-20). rs198358 was directly genotyped with 99.25% success. The estimated allele dose at rs5068, rs632793, and rs198389 was imputed using the MACH 1.0.16 program ( and data from HapMap (2123 ). Imputation quality scores ranged from 0.962 (rs632793) to 0.998 (rs5068).


Prospective association of NT-proBNP and T2DM. Data for this component of the study were analyzed as a case-cohort study using appropriate weighting of the observations (24, 25). Because sampling was stratified by race/ethnicity and age, we used stratum-specific weighting (26). Overall population characteristics were estimated using weights equal to the inverse of the inclusion probabilities in the subcohort sample using the Horvitz-Thompson weighting approach in Proc SurveyMeans in SAS 9.2 (24, 27). Crude frequencies and median [interquartile range (IQR)] values of baseline clinical and biochemical characteristics were compared using [chi square] and Wilcoxon rank-sum tests. Estimated population frequencies of categorical variables were compared using the Rao-Scott [chi square] test in Proc SurveyFreq in SAS 9.2. Estimated population means for continuous variables in the cases and subcohort were compared using weighted linear regression in Proc SurveyReg in SAS 9.2. Associations between NTproBNP and other serum metabolic markers, including Hb [A.sub.1c], creatinine, estimated glomerular filtration rate (eGFR), insulin, ghrelin, and adiponectin, were computed in the subcohort using Spearman correlation coefficients.

NT-proBNP concentrations were divided into increasing quartiles based on the distribution in the reference subcohort of nondiabetic women. Cox proportional hazards models adjusted for the weighted sample size (28) were used to calculate adjusted hazard ratios (HRs) and 95% CIs for incident T2DM according to the increasing quartile of NT-proBNP, with the lowest quartile chosen as the referent category. Tests for trend across quartiles of NT-proBNP were calculated using an indicator variable set to the median value of each quartile of NT-proBNP. We also assessed the association between NT-proBNP and incident diabetes modeled per 1SD increment on the natural logarithm-transformed scale. Women without complete information for all covariables included in multivariable models were excluded from those analyses. A maximum number of 27 women were excluded from the primary analysis for missing covariate information.

Because the results of the primary analysis described above suggested the possibility of a threshold effect, we conducted an exploratory analysis in which we analyzed several NT-proBNP concentrations as possible dichotomous cutpoints for association with T2DM. The primary analysis suggested the 75th percentile (117.4 ng/L) would be a possible cutpoint; we then selected the NT-proBNP value corresponding to the 50th, 55th, 60th, 65th, 70th, 80th, 85th, and 90th percentiles of the NT-proBNP distribution in the reference subcohort. The risk of T2DM for women with values at or above each threshold were compared to a reference group comprised of women with NTproBNP values <50th percentile using adjusted Cox proportional hazards models as described for the primary analysis. We also performed sensitivity analyses that censored women at the time when they developed cardiovascular disease (n = 14) or congestive heart failure (n = 8) before either developing diabetes or the close of follow-up. All analyses were performed using SAS 9.1 or 9.2 for Unix.

Common variants in NPPA-NPPB and NT-proBNP Concentrations. Linear regression models adjusted for age, BMI, systolic blood pressure, and subject selection criteria (prevalent T2DM, incident T2DM, incident cardiovascular disease, both incident cardiovascular disease and T2DM, or subcohort) were used to test for evidence of association between rs198358, rs5068, rs632793, and rs198389 and natural logarithm-transformed NT-proBNP concentrations in the reference subcohort. Each SNP was tested for evidence of association with BMI, systolic blood pressure, and fasting insulin concentration. Evidence for deviation of an additive mode of inheritance was evaluated by including a term to test for nonlinearity in the linear regression model.

Common variants in NPPA-NPPB and Incident T2DM. Cox proportional hazards models were constructed to test for evidence of association between rs198358, rs5068, rs632793, and rs198389 and incident T2DM. Models were adjusted for age, BMI, (BMI)2, hormone therapy use, family history of diabetes, exercise at least once per week, and alcohol use at least 1 drink per day. Each SNP was tested for evidence of association with BMI, hormone therapy use, family history of diabetes, exercise, and alcohol use. Evidence for deviation of an additive mode of inheritance was evaluated by including a term to test for nonlinearity in the proportional hazards regression model.



Baseline characteristics of the women who subsequently developed T2DM and the women selected for inclusion in the reference subcohort, both in crude analyses and after reweighting to reflect sampling from the larger WHS population, are displayed in Table 1. As anticipated, in both crude and reweighted analyses, women who developed T2DM had higher BMI and blood pressure, were more likely to have a family history of diabetes, drank alcohol and exercised less frequently, and had higher fasting insulin and hsCRP concentrations (each P < 0.0001). In both the crude and reweighted analyses, NT-proBNP concentrations were lower among the women who subsequently developed T2DM (each P < 0.001). The median (IQR) duration of follow-up for all women included in the case-cohort sample was 13.4 (7.7-11.6) years.

Correlations between baseline concentrations of NT-proBNP and baseline anthropometric, metabolic, lipid, and inflammatory biomarkers in the reference subcohort are displayed in Table 2. In the unadjusted analysis, age (0.37), insulin (-0.25) and leptin (-0.18) appeared to be at least as closely correlated with NTproBNP concentrations as other known correlates, including BMI (-0.17), blood pressure (0.06), and eGFR (-0.20). After adjusting for age, and for age and BMI, correlations between NT-proBNP and insulin persisted (-0.25 and -0.18, respectively). Neither Hb [A.sub.1c] nor any of the inflammatory biomarkers showed any important correlations with NT-proBNP.

The risk of incident T2DM according to increasing quartiles of NT-proBNP concentrations is displayed in Table 3. In models adjusted for age and race, increasing concentrations of NT-proBNP were associated with a reduced risk of incident T2DM for quartiles 2-4 compared with quartile 1. After adjusting for BMI, the observed reductions in the risk ofT2DM were attenuated in quartiles 2-4 but remained statistically significant for the highest as compared to the lowest category of NT-proBNP (HR 0.54, 95% CI 0.33-0.89, P = 0.015). This relationship persisted after adjustment for eGFR, hormone therapy use, family history of diabetes, physical activity, and alcohol consumption (HR 0.51, 95% CI 0.30-0.86, P = 0.011) and was attenuated by further adjusting for baseline insulin concentrations (HR 0.58, 95% CI 0.35-0.97, P = 0.039). We observed a 20% reduction in the risk of incident T2DM per 1SD unit increase in natural logarithm-transformed NT-proBNP concentrations in fully adjusted models (Table 3, Model 4; HR 0.80, 95% CI 0.67-0.96, P = 0.016). This point estimate did not change substantially when Hb [A.sub.1c] was added to the model (HR 0.80, 95% CI 0.65-0.99, P = 0.044). No significant change in the risk estimates was noted after further adjusting for hsCRP or after substituting alternative measures of adiposity (waist circumference, hip circumference, or waist-to-hip ratio) for BMI in adjusted models (data not shown).

The results of the categorical analysis suggested the possibility of a threshold effect, in which only women with the highest NT-proBNP concentrations were at reduced risk of T2DM. In an exploratory analysis, we examined the risk of incident T2DM for women with NT-proBNP concentrations at or above the 55th through the 90th percentiles, using women with NTproBNP concentrations <50th percentile (<65.2 ng/L) as the referent group (Fig. 1). As can be seen, the association with incident T2DM is statistically significant for NT-proBNP cutpoints of the 75th percentile and higher. For example, women with NT-proBNP concentrations >75th percentile (117.4 ng/L) were at 47% lower risk of T2DM (HR 0.53, 95% CI 0.33-0.86, P = 0.009) than those with NT-proBNP concentrations below the median after adjustment for all confounders but insulin. Further adjustment for insulin did not substantially alter the results (HR 0.58, 95% CI 0.36-0.93, P = 0.024).

We did not observe any evidence of statistical interaction between NT-proBNP concentrations above or below this threshold and WHO category of BMI (<25, 25 to <30, 30+ kg/[m.sup.2]), family history of diabetes, systolic blood pressure, or age above or below 53 years (the median in the study population). In a sensitivity analysis, we constructed separate proportional hazards models that censored women when they developed either incident cardiovascular disease or congestive heart failure. Our results remained unchanged.



The results for the test of association between SNPs rs198358, rs5068, rs632793, and rs198389 are displayed in Table 4. As can be seen, we observed statistically significant evidence of association between natural logarithm-transformed baseline NT-proBNP concentrations and rs632792 and rs198389. Each copy of the minor allele at each SNP increased natural logarithm-transformed NT-proBNP concentrations by 0.2012 and 0.1860 SD units, respectively. No statistically significant evidence of deviation from an additive mode of inheritance was detected for any of the SNPs. Although none of the SNPs was significantly related to blood pressure, we did detect a statistically significant association between BMI and rs632792 [[beta] (SE) per 1 kg/[m.sup.2] increase in BMI = -0.69682 (0.33556), P = 0.038] andrs198389 [-0.66137(0.32973),P = 0.046]. Including an interaction term between each SNP and BMI in linear regression models of natural logarithm-transformed NT-proBNP concentrations did not improve model fit.


When each of the 4 SNPs was tested for evidence of association with incident T2DM in adjusted Cox models (n = 22607 with 1372 cases of incident T2DM), we observed evidence of association for both rs632793 and rs198389. The per-allele hazard ratio for T2DM was 0.91 (95% CI 0.84-0.989; P = 0.026) for rs632793 and 0.92 (95% CI 0.85-0.995;P = 0.036) for rs198389. The effect of SNPs at either rs632793 or rs198389 on T2DM risk is consistent with the direction of their effect on NT-proBNP concentrations. However, we observed no statistically significant association for either rs198358 (per-allele HR 0.94, 95% CI 0.86-1.03, P = 0.18) or rs5068 (per-allele HR 0.98, 95% CI 0.83-1.16, P = 0.84). No statistically significant evidence of deviation from an additive mode of inheritance was detected for any of the SNPs, and no significant associations with BMI, family history of diabetes, exercise, hormone therapy use, or alcohol use were noted.


In these prospective analyses, we report a statistically robust association between concentrations of NTproBNP and the risk of incident diabetes in a population of initially healthy women at usual risk for T2DM. We observed a nearly 50% reduction in the risk of type 2 diabetes among women with NT-proBNP concentrations > 117 ng/L (the 75th percentile), a concentration that is both well within the reference interval and routinely observed in clinical practice. This reduced risk cannot be attributed to intervening congestive heart failure or coronary heart disease occurring during follow-up. Furthermore, while we observed the expected associations between NT-proBNP concentrations and age and BMI, we also observed an inverse relationship between NT-proBNP and fasting insulin that persisted after adjusting for age and BMI. We also confirmed previously reported associations between common variation in the NPPA-NPPB gene and NTproBNP concentrations, and an association between 2 SNPs in NPPA-NPPB and incident T2DM in initially healthy women. The direction of these effects was consistent with data we report here for the association between plasma NT-proBNP and the risk of incident T2DM.

These data, taken together, lend support to the hypothesis that natriuretic peptides are causally involved in the development of insulin resistance and clinical diabetes. The magnitude of risk reduction observed is consistent with that observed by Pfister et al. (10) in the EPIC-Norfolk cohort, who reported a 21% reduction in the adjusted risk of incident T2DMper 1-unitSDincrease in natural logarithm-transformed NT-proBNP concentrations (HR 0.79, 95% CI 0.64-0.97, P = 0.02). In that same report (10), Pfister et al. performed a Mendelian randomization analysis that supports a causal role for natriuretic peptides in the development of T2DM. Our observations support that conclusion, and suggest that alterations in NT-proBNP concentrations precede the clinical diagnosis of diabetes by many years. Other prospective studies have reported similar results, with one study reporting significant associations between B-type natriuretic peptide concentrations, NT-proBNP concentrations, and midregional atrial natriuretic peptide concentrations and incident T2DM (11) and another reporting a significant association for midregional atrial natriuretic peptide but not NT-proBNP (12). Cross-sectional studies have also reported inverse associations between natriuretic peptides and features of the metabolic syndrome (7-9).

Our prospective study adds to this previously published work by closely examining the relationships between NT-proBNP and hormones with important metabolic functions, including insulin, leptin, and ghrelin. We observed a modest inverse correlation between NT-proBNP and fasting insulin concentrations that was independent of BMI and appeared to be stronger than its correlation with blood pressure, a traditionally accepted determinant of natriuretic peptide concentrations. In our study, the relationship between NT-proBNP and incident T2DM is independent of both BMI and fasting insulin concentrations, supporting the hypothesis that alterations in NT-proBNP concentrations contribute to T2DM risk via a different biological mechanism or with different timing than alterations in insulin sensitivity or obesity.

We were also able to replicate the results of several genetic studies that reported significant associations between common variation in the NPPA-NPPB gene and NT-proBNP concentrations, blood pressure, and prevalent T2DM (17-20). Our results are largely consistent with those previously published findings, as 3 of the 4 SNPs previously reported to associate with NTproBNP concentrations were also associated with NTproBNP concentrations in our cohort. The fourth, rs5068, has shown less consistent association with BNP concentrations (19, 20). We also replicated previously published cross-sectional associations between variation in NPPA-NPPB and prevalent T2DM (17,18).In our prospective analysis of 1372 cases of incident T2DM, we observed a statistically significant association between two closely linked SNPs [rs632793 and rs198389, [r.sup.2] = 0.874 and D'= 1.00 in the participants of European ancestry included in 1000 Genomes (29)] in the NPPA-NPPB gene and T2DM.

A possible causal link between natriuretic peptides and T2DM is supported by evidence from experimental mouse models of altered natriuretic peptide expression. In recent work by Miyashita et al. (30), transgenic mice that expressed BNP at levels > 100 times normal were leaner, were resistant to the effects of a high-fat diet on weight gain and insulin resistance, and had lower total body fat and increased oxygen consumption. These effects were mediated by increased mitochondrial biogenesis through a natriuretic peptide-activated cGMP signaling pathway. Furthermore, natriuretic peptide receptors are expressed in pancreatic [beta]-cells and modulate glucose-stimulated insulin secretion (31, 32).

Although our study is prospective, the possibility of reverse causality cannot be excluded. In particular, we observed a modest inverse correlation between NTproBNP concentrations and fasting insulin concentrations at baseline, and physiologic evidence of insulin resistance can precede clinical signs of T2DM by 3-6 years (33). However, the median time to clinical diabetes in our cohort was 8.2 years, and the association between NT-proBNP and incident T2DM was independent of insulin concentrations, suggesting that the 2 hormones may mark different pathophysiologic processes on the path to T2DM. We also observed an inverse correlation between BMI and NT-proBNP concentrations, as have others (9). Our prospective data raise the possibility that the relationship between natriuretic peptide concentrations and altered metabolism is not completely mediated by obesity, although overlapping biologic pathways are difficult to exclude. Finally, we observed no attenuation of the relationship between NT-proBNP and T2DM after adjusting for subclinical inflammation, which is an important risk marker for T2DM, suggesting that natriuretic peptides act to alter T2DM risk by an alternative mechanism (34).

In conclusion, we observed a >40% reduction in the risk of incident type 2 diabetes among initially healthy women with NT-proBNP concentrations > 117 ng/L. This association was independent of other traditional risk factors for diabetes, including BMI, kidney function, age, and fasting insulin concentrations. We also replicate published reports of associations between common variation in the NPPANPPB genes and both NT-proBNP concentrations and the risk of T2DM. These prospective data offer strong support for the hypothesis that the natriuretic peptide system plays an important role in glucose and fatty acid metabolism and in the development of type 2 diabetes.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: D.I. Chasman, Brigham & Women's Hospital; M.C. Magnone, F. Hoffman-La Roche; M. Bobadilla, F. Hoffman-La Roche; N. Rifai, Clinical Chemistry, AACC.

Consultant or Advisory Role: None declared.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: This study was supported by grants HL043851, HL-080467, and HL-099355 from the National Heart, Lung, and Blood Institute and CA-047988 from the National Cancer Institute, the Donald W. Reynolds Foundation (Las Vegas, NV), the Leducq Foundation (Paris, France), and the Doris Duke Charitable Foundation (New York, NY). Genotyping was provided by Amgen (Cambridge, MA). B.M. Everett (PI), investigator-initiated grant from Roche Diagnostics (measurement of NT-proBNP concentrations), Scientist Development Grant from the American Heart Association (0835304N), and Discovery Award from the Brigham and Women's Hospital Cardiovascular Leadership Council; D.I. Chasman, NIH; M.C. Magnone, F. Hoffman-La Roche; M. Bobadilla, F. Hoffman-La Roche; P.M Ridker, investigator-initiated grant from Roche Pharma (support for the construction of the case-cohort study).

Expert Testimony: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.


(1.) de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.

(2.) Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.

(3.) Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-7.

(4.) Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.

(5.) Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000;14: 1345-51.

(6.) Lafontan M, Moro C, Sengenes C, Galitzky J, Crampes F, Berlan M. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Arterioscler Thromb Vasc Biol 2005;25:2032-42.

(7.) Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.

(8.) Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46: 660-6.

(9.) Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007;115:1345-53.

(10.) Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med 2011;8:e1001112.

(11.) Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One 2010;5:e10100.

(12.) Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the Prospective Malmo Diet and Cancer Study. J Clin Endocrinol Metab 2012;97:638-45.

(13.) Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.

(14.) Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, et al. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy American women. Clin Chem 2008;54:249-55.

(15.) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.

(16.) Ding EL, Song Y, Manson JE, Pradhan AD, Buring JE, Liu S. Accuracy of administrative coding for type 2 diabetes in children, adolescents, and young adults. Diabetes Care 2007;30:e98;author reply e9.

(17.) Meirhaeghe A, Sandhu MS, McCarthy MI, de Groote P, Cottel D, Arveiler D, et al. Association between the t-381c polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 2007;16:1343-50.

(18.) Choquet H, Cavalcanti-Proenca C, Lecoeur C, Dina C, Cauchi S, Vaxillaire M, et al. The t-381c SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects. Hum Mol Genet 2009;18:2495-501.

(19.) Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009;41:348-53.

(20.) Cannone V, Boerrigter G, Cataliotti A, Costello Boerrigter LC, Olson TM, McKie PM, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 2011;58:629-36.

(21.) International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-61.

(22.) Pei YF, Li J, Zhang L, Papasian CJ, Deng HW. Analyses and comparison of accuracy of different genotype imputation methods. PloS One 2008;3: e3551.

(23.) Li Y, Ding J, Abecasis GR. Mach 1.0: rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet 2006;S79:2290.

(24.) Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11.

(25.) Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994;50:1064-72.

(26.) Borgan O, Langholz B, Samuelsen SO, Goldstein L, Pogoda J. Exposure stratified case-cohort designs. Lifetime Data Anal 2000;6:39-58.

(27.) Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. J Am Stat Assoc 1952;47:663-85.

(28.) Langholz B, Jiao J. Computational methods for case-cohort studies. Comp Stats Data Analysis 2007;51:3737-48.

(29.) A map of human genome variation from population-scale sequencing. Nature 2010;467: 1061-73.

(30.) Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, et al. Natriuretic peptides/ cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009;58:2880-92.

(31.) Soriano S, Ropero AB, Alonso-Magdalena P, Ripoll C, Quesada I, Gassner B, et al. Rapid regulation of K(ATP) channel activity by 17betaestradiol in pancreatic beta-cells involves the estrogen receptor beta and the atrial natriuretic peptide receptor. Mol Endocrinol 2009;23:1973-82.

(32.) Ropero AB, Soriano S, Tuduri E, Marroqui L, Tellez N, Gassner B, et al. The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. Endocrinology 2010;151: 3665-74.

(33.) Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373:2215-21.

(34.) Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.

Brendan M. Everett, [1,2] * Nancy R. Cook, [1] Daniel I. Chasman, [1] Maria C. Magnone, [3] Maria Bobadilla, [3] Nader Rifai, [4] Paul M Ridker, [1,2] and Aruna D. Pradhan [1,5]

[1] Division of Preventive Medicine,2 Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;3 F. Hoffman-La Roche, Pharma, Metabolic and Vascular Diseases, Basel, Switzerland; 4 Division of Laboratory Medicine, Department of Pathology, Children's Hospital, Boston, MA; 5 Division of Cardiovascular Medicine, VA Boston Medical Center, Boston, MA.

* Address correspondence to this author at: Brendan M. Everett, Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave., Boston, MA 02115. Fax 617-232-3541; e-mail:

Received August 1, 2012; accepted November 27, 2012.

Previously published online at DOI: 10.1373/clinchem.2012.194167

[6] Nonstandard abbreviations: BNP, B-type natriuretic peptide; NT-proBNP, amino-terminal pro-BNP; BMI, body mass index; T2DM, type 2 diabetes mellitus; WHS, Women's Health Study; Hb A1c, hemoglobin A1c; hsCRP, high-sensitivity C-reactive protein; SNP, single nucleotide polymorphism; IQR, interquartile range; eGFR, estimated glomerular filtration rate; HR, hazard ratio.

[7] Human genes: NPPA, natriuretic peptide A; NPPB, natriuretic peptide B.
Table 1. Comparisons of baseline characteristics of T2DM cases
and the random subcohort, in the sample and reweighted to the
total WHS cohort. (a)


     Baseline Characteristics           Diabetes Cases

n                                     491
Age, years                             53.3 (49.0-59.8)
White race                              450 (92)
BMI, kg/[m.sup.2]                      29.4 (25.8-33.9)
Blood pressure, mmHg                    135 (125-145)
Current smoking                          63 (12.9)
Family history of diabetes              208 (42.4)
Alcohol use [greater than or
  equal to] 1 drink per day              27 (5.5)
Exercise [greater than or equal
  to] 1 times per week                  159 (32.4)
Hormone therapy use                     209 (42.7)
Randomized aspirin use                  248 (50.5)
eGFR, mL x [min.sup.-1] x
  [(1.73 [m.sup.2]).sup.-1]           112.5 (92.4-141.7)
Hb [A.sub.1c], %                        5.3 (5.1-5.5)
Fasting insulin, [micro]IU/mL          12.5 (8.4-18.9)
hsCRP, mg/L                             4.0 (2.2-7.0)
NT-proBNP, ng/L                        46.8 (26.1-83.2)
ln(NT-proBNP)                           3.9 (3.3-4.4)


     Baseline Characteristics              Subcohort           P

n                                     561
Age, years                              56.7 (50.9-64.2)    <0.0001
White race                               516 (92)            0.37
BMI, kg/[m.sup.2]                       25.6 (23.0-28.3)    <0.0001
Blood pressure, mmHg                     125 (115-135)      <0.0001
Current smoking                           56 (10.0)          0.18
Family history of diabetes               158 (28.2)         <0.0001
Alcohol use [greater than or
  equal to] 1 drink per day               45 (8.0)           0.06
Exercise [greater than or equal
  to] 1 times per week                   259 (46.2)         <0.0001
Hormone therapy use                      242 (43.3)          0.60
Randomized aspirin use                   275 (49.0)          0.66
eGFR, mL x [min.sup.-1] x
  [(1.73 [m.sup.2]).sup.-1]             92.6 (7584-110.6)   <0.0001
Hb [A.sub.1c], %                         5.0 (4.9-5.2)      <0.0001
Fasting insulin, [micro]IU/mL            6.8 (4.4-10.7)     <0.0001
hsCRP, mg/L                              2.2 (0.9-4.6)      <0.0001
NT-proBNP, ng/L                         65.2 (37.8-117.4)   <0.0001
ln(NT-proBNP)                            4.2 (3.7-4.8)      <0.0001

                                      Reweighted to Population

     Baseline Characteristics              Diabetes Cases

n                                     1228
Age, years                              53.6 (49.3-59.7)
White race                              1134 (92.4)
BMI, kg/[m.sup.2]                       29.6 (26.0-33.9)
Blood pressure, mmHg                     135 (125-145)
Current smoking                          159 (12.9)
Family history of diabetes               520 (42.3)
Alcohol use [greater than or
  equal to] 1 drink per day              361 (29.4)
Exercise [greater than or equal
  to] 1 times per week                   399 (32.5)
Hormone therapy use                      533 (43.5)
Randomized aspirin use                   617 (50.2)
eGFR, mL x [min.sup.-1] x
  [(1.73 [m.sup.2]).sup.-1]            112.7 (92.6-141.7)
Hb [A.sub.1c], %                         5.3 (5.1-5.5)
Fasting insulin, [micro]IU/mL           12.5 (8.4-18.8)
hsCRP, mg/L                              4.1 (2.3-7.0)
NT-proBNP, ng/L                         46.9 (26.4-83.1)
ln(NT-proBNP)                            3.9 (3.3-4.4)

                                         Reweighted to Population

     Baseline Characteristics              Subcohort           P

n                                     19277
Age, years                              53.5 (49.2-59.3)     0.53
White race                             18468 (95.8)
BMI, kg/[m.sup.2]                       25.6 (22.9-28.3)    <0.0001
Blood pressure, mmHg                     125 (115-135)      <0.0001
Current smoking                         1999 (10.4)          0.29
Family history of diabetes              5178 (26.9)         <0.0001
Alcohol use [greater than or
  equal to] 1 drink per day             7749 (40.2)          0.0001
Exercise [greater than or equal
  to] 1 times per week                  8991 (46.6)         <0.0001
Hormone therapy use                     8379 (43.6)          0.80
Randomized aspirin use                  9312 (48.3)          0.41
eGFR, mL x [min.sup.-1] x
  [(1.73 [m.sup.2]).sup.-1]             96.1 (80.5-115.7)   <0.0001
Hb [A.sub.1c], %                         5.0 (4.8-5.2)      <0.0001
Fasting insulin, [micro]IU/mL            6.9 (4.3-10.7)     <0.0001
hsCRP, mg/L                              2.1 (0.9-4.5)      <0.0001
NT-proBNP, ng/L                         58.7 (35.2-103.5)   <0.0001
ln(NT-proBNP)                            4.1 (3.6-4.6)      <0.001

(a) Data are median (IQR) or n (%).

Table 2. Spearman correlations between NT-proBNP and other
metabolic biomarkers in the reference subcohort, a representative
subsample of the WHS.

                                       Unadjusted        Age-Adjusted

Characteristic or Biomarker         [rho]       P      [rho]       P

Age, years                           0.371   <0.0001
BMI, kg/[m.sup.2]                   -0.165   <0.0001   -0.185   <0.0001
Systolic blood pressure, mmHg        0.059    0.17     -0.044    0.30
Metabolic biomarkers
  Insulin, [micro]IU/mL             -0.245   <0.0001   -0.248   <0.0001
  Hb [A.sub.1c], %                  -0.039    0.36     -0.106    0.01
  Ghrelin, pg/mL                     0.051    0.23      0.051    0.23
  Leptin, ng/mL                     -0.177   <0.0001   -0.178   <0.0001
  Resistin, ng/mL                   -0.033    0.43     -0.073    0.08
  Creatinine, mg/dL                 -0.014    0.74     -0.054    0.20
  eGFR, mL x [min.sup.-1] x
    [(1.73 [m.sup.2]).sup.-1]       -0.195   <0.0001   -0.048    0.26
Lipid biomarkers
  Total cholesterol, mg/dL          -0.130    0.002    -0.209   <0.0001
  LDL cholesterol, mg/dL            -0.151    0.0004   -0.228   <0.0001
  Oxidized LDL cholesterol          -0.027    0.52     -0.087    0.04
  HDL cholesterol, mg/dL             0.143    0.0007    0.132    0.002
  Triglycerides, mg/dL              -0.110    0.009    -0.148    0.0005
  Free fatty acids mEq/L             0.031    0.46     -0.048    0.26
Inflammatory biomarkers
  hsCRP, mg/L                        0.016    0.70     -0.026    0.54
  IL-6, pg/mL                        0.076    0.07     -0.009    0.83
  Soluble intracellular adhesion
    molecule 1, ng/mL                0.006    0.89     -0.090    0.03

                                        Age and

Characteristic or Biomarker         [rho]       P

Age, years
BMI, kg/[m.sup.2]
Systolic blood pressure, mmHg        0.025    0.57
Metabolic biomarkers
  Insulin, [micro]IU/mL             -0.180   <0.0001
  Hb [A.sub.1c], %                  -0.069    0.10
  Ghrelin, pg/mL                    -0.015    0.72
  Leptin, ng/mL                     -0.070    0.10
  Resistin, ng/mL                   -0.051    0.23
  Creatinine, mg/dL                 -0.052    0.22
  eGFR, mL x [min.sup.-1] x
    [(1.73 [m.sup.2]).sup.-1]        0.070    0.10
Lipid biomarkers
  Total cholesterol, mg/dL          -0.196   <0.0001
  LDL cholesterol, mg/dL            -0.202   <0.0001
  Oxidized LDL cholesterol          -0.054    0.21
  HDL cholesterol, mg/dL             0.070    0.10
  Triglycerides, mg/dL              -0.098    0.02
  Free fatty acids mEq/L            -0.022    0.61
Inflammatory biomarkers
  hsCRP, mg/L                        0.050    0.24
  IL-6, pg/mL                        0.047    0.27
  Soluble intracellular adhesion
    molecule 1, ng/mL               -0.061    0.15

Table 3. Risk of incident diabetes according to baseline
concentration of NT-proBNP. (a)

Model              Quartile 1      Quartile 2         Quartile 3

NT-proBNP range,
  ng/L               <37.4       37.4 to <64.2      64.2 to <117.0
Model 1               1.0       0.56 (0.40-0.78)   0.61 (0.43-0.85)
  P value                            0.0006             0.004
Model 2               1.0       0.84 (0.56-1.26)   0.93 (0.61-1.42)
  P value                             0.40               0.75
Model 3               1.0       0.88 (0.58-1.34)   0.97 (0.62-1.51)
  P value                             0.56               0.89
Model 4               1.0       0.96 (0.63-1.47)   0.99 (0.63-1.56)
  P value                             0.86               0.97

Model                 Quartile 4      P trend   Per 1 unit SD (b)

NT-proBNP range,
  ng/L                  >117.4
Model 1            0.40 (0.27-0.60)   <0.001    0.68 (0.58-0.79)
  P value              <0.0001                       <0.001
Model 2            0.54 (0.33-0.89)    0.047    0.79 (0.67-0.94)
  P value               0.015                         0.007
Model 3            0.51 (0.30-0.86)    0.041    0.78 (0.65-0.93)
  P value               0.011                         0.006
Model 4            0.58 (0.35-0.97)    0.10     0.80 (0.67-0.96)
  P value               0.039                         0.016

(a) Model 1, adjusted for age and race; model 2, model 1 plus BMI
(kg/[m.sup.2]) and [(BMI).sup.2]; model 3, model 2 plus eGFR,
hormone therapy use, family history of diabetes, exercise at least
once per week, alcohol use at least 1 drink per day; model 4, model
3 plus insulin ([micro]IU/mL).

(b) Of the natural logarithm-transformed NT-proBNP value.

Table 4. Association of common variants in the NPPA-NPPB region
with natural logarithm-transformed NT-proBNP concentrations. (a)

                                         Minor/Major   Minor Allele
SNP            Chromosome    Position      Allele      Frequency (c)

rs198358 (d)       1         11826663        C/T           0.236
rs5068             1         11828561        G/A           0.059
rs632793           1         11833264        G/A           0.409
rs198389           1         11841858        G/A           0.427

                                 Association (b)

SNP            Quality Score     [beta] (SE)        P

rs198358 (d)        N/A         0.0829 (0.0680)   0.228
rs5068             0.998       -0.0035 (0.1255)   0.978
rs632793           0.962        0.2012 (0.0631)   0.0015
rs198389           0.987        0.1860 (0.0620)   0.0029

(a) For each of the SNPs, the smallest P value was seen when an
additive (rather than dominant) mode of inheritance was assumed.

(b) Per-allele association with 1SD change in natural
logarithm-transformed NT-proBNP concentrations, adjusted for age,
BMI, and systolic blood pressure The mean (SD) natural
logarithm-transformed NT-proBNP concentration in the reference
subcohort is 4.254 (0.821).

(c) In the participants of European descent with available
genotyping information and NT-proBNP concentrations. rs198358 was
directly genotyped; genotyping information for the remaining SNPs
was imputed.

(d) Test of association used directly measured genotypes. The
results did not differ when missing genotypes at rs198358 (n = 1,
or 0.22%) were replaced with the imputed estimated genotype dose.
COPYRIGHT 2013 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Endocrinology and Metabolism
Author:Everett, Brendan M.; Cook, Nancy R.; Chasman, Daniel I.; Magnone, Maria C.; Bobadilla, Maria; Rifai,
Publication:Clinical Chemistry
Article Type:Report
Date:Mar 1, 2013
Previous Article:Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass...
Next Article:Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters